In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease (Q44266812)

1 December 2017

In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease (English)

1 reference

1 December 2017

0 references

0 references

5

Alvaro J Romanha

1 reference

1 December 2017

Julio A Urbina

1

1 reference

1 December 2017

Gilberto Payares

series ordinal

2

1 reference

1 December 2017

Cristina Sanoja

series ordinal

3

1 reference

1 December 2017

Renee Lira

series ordinal

4

1 reference

1 December 2017

1 January 2003

1 reference

International Journal of Antimicrobial Agents

1 December 2017

1 reference

1 December 2017

21

1 reference

1 December 2017

27-38

1 reference

1 December 2017

1

1 reference

Chemotherapy of Chagas' disease: the how and the why.

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Parasitological cure of Chagas disease: is it possible? Is it relevant?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Specific treatment of Chagas disease: current status and new developments

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Chemotherapy of Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vitro activities of four novel triazoles against Scedosporium spp

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Azole cross-resistance in Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vitro antifungal susceptibilities of Trichosporon species.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Cure of short- and long-term experimental Chagas' disease using D0870

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Ultrastructural alterations induced by ICI 195,739, a bis-triazole derivative with strong antiproliferative action against Trypanosoma (Schizotrypanum) cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

An experimental and clinical assay with ketoconazole in the treatment of Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Failure of ketoconazole to cure chronic murine Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900273-X

7 January 2021

10.1016/S0924-8579(02)00273-X

Identifiers

DOI

1 reference

1 December 2017

1 reference